Evidence map›Paper›PMID 32495301›Full record

ReviewCurrent atherosclerosis reports2020

New Pharmacological Approaches to Target PCSK9.

Alberico L Catapano, Angela Pirillo, Giuseppe D Norata

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Lipid Lowering Drugs in Acute Coronary Syndromes (ACS).Current atherosclerosis reports · 2023
    Review
  12. The evolving landscape of PCSK9 inhibition in cancer.European journal of pharmacology · 2023
    Review
  13. Article
  14. Inclisiran: A Review in Hypercholesterolemia.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
  15. Article
  16. Review
  17. Inclisiran: How Widely and When Should We Use It?Current atherosclerosis reports · 2022
    Review
  18. Article
  19. Review
  20. The Multifaceted Biology of PCSK9.Endocrine reviews · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alberico L CatapanoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Angela PirilloIRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy.
Giuseppe D NorataDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. danilo.norata@unimi.it.
MultiMedica · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewProprotein convertase subtilisin kexin 9 (PCSK9) plays a crucial role in regulating circulating levels of LDL-C as a consequence of its ability to inhibit LDL receptor recycling in the liver. Loss of function variants in the PCSK9 gene result in low LDL-C levels and associate with reduced cardiovascular risk, whereas gain of-function variants associate with hypercholesterolemia and increased risk of early cardiovascular events. Thus, PCSK9 inhibition has been established as an additional approach for the treatment of hypercholesterolemia. The aim of this review is to provide a brief overview of current strategies targeting PCSK9 and discuss clinical results of the emerging approaches. RECENT

findingsTwo monoclonal antibodies targeting circulating PCSK9 (evolocumab and alirocumab) have been approved for the treatment of hypercholesterolemia and cardiovascular disease. Later, a gene silencing approach (inclisiran), which inhibits hepatic PCSK9 synthesis, was shown to be as effective as monoclonal antibodies but with a twice a year injection and is currently under evaluation for approval. Due to the elevated costs of such therapies, several other approaches have been explored, including peptide-based anti PCSK9 vaccination, and small oral PCSK9 inhibitors, which are still in preclinical phase. In the coming years, we will assist to a progressive introduction of novel anti-PCSK9 approaches in the clinical practice for the treatment of patients with hypercholesterolemia as well as patients at high cardiovascular risk.

Indexed as

PCSK9 InhibitorsAnimalsAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLHumansHypercholesterolemiaProprotein Convertase 9Receptors, LDLRisk FactorsRNA, Small InterferingSerine Proteinase InhibitorsTreatment OutcomealirocumabALN-PCSAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLevolocumabLDLR protein, humanPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Receptors, LDLRNA, Small InterferingSerine Proteinase InhibitorsGene silencingHypercholesterolemiaMonoclonal antibodiesPCSK9PCSK9 inhibition

Identifiers

PMID32495301
OpenAlexW3028874808

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.